57 results
Page 2 of 3
8-K
EX-99.1
tradmmeb ae0h7lz
17 Feb 22
Longeveron Adds Seasoned Biotech Executive Todd Girolamo to Its Board of Directors
4:02pm
8-K
EX-99.1
0l79 dh4f6qf
10 Jan 22
Regulation FD Disclosure
10:38am
424B3
nym8y3
22 Dec 21
Prospectus supplement
5:07pm
8-K
EX-99.1
wfj6 xohm
7 Dec 21
Regulation FD Disclosure
4:51pm
8-K
EX-99.1
j22bunlirtblg168v9
3 Dec 21
Longeveron Inc. Announces Pricing of a $20.5 Million Private Placement
5:13pm
8-K
EX-99.2
8ucne ps7mz1h1f3a2l
3 Dec 21
Longeveron Inc. Announces Pricing of a $20.5 Million Private Placement
5:13pm
8-K
EX-99.1
bghapso8dzo5wi
18 Nov 21
U.S. Food and Drug Administration Approves Longeveron’s Lomecel-B for Rare Pediatric Disease Designation to Treat
4:58pm
8-K
EX-99.1
laokhf8sh7
12 Nov 21
Longeveron Inc. Provides Corporate Update and Reports Third Quarter 2021 Financial Results
8:00am
8-K
EX-99.1
fu9 4y9ctdw7
1 Oct 21
Regulation FD Disclosure
4:02pm
8-K
EX-99.2
9a5zi95t0ajn05ht5hj
1 Oct 21
Regulation FD Disclosure
4:02pm
8-K
EX-99.1
kiwrway
9 Sep 21
Regulation FD Disclosure
9:28am
8-K
EX-99.1
cq4ivmp tbl6uo
13 Aug 21
Longeveron Announces Topline Results of Phase 2b Study of Lomecel-B for Aging Frailty
1:46pm
8-K
1cgze241
13 Aug 21
Longeveron Announces Topline Results of Phase 2b Study of Lomecel-B for Aging Frailty
1:46pm
8-K
EX-99.1
pr5 soa36c
13 Aug 21
Longeveron Inc. Provides Corporate Update and Reports Second Quarter 2021 Financial Results
10:32am
8-K
EX-99.1
725wsnpb5tgko
25 May 21
Longeveron Announces the Appointment of Ursula Ungaro to its Board of Directors
10:15am
10-Q
hp2mqh3fdykr56igk
14 May 21
Quarterly report
4:08pm
8-K
EX-99.1
fm32agrj6wk 8yxlwbt2
14 May 21
Results of Operations and Financial Condition
8:54am